Tango Biosciences scientists, in collaboration with colleagues from B2S Life Sciences, LifeTein, and Euprotein, publish a scientific report on generating recombinant affinity reagents (monobodies) to the receptor binding domain (RBD) of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. Soluble forms of the monobodies bound to several different preparations of the RBD and the S1 spike subunit, with affinities ranging from 3 to 14 nM as measured by bio-layer interferometry. All four monobodies successfully bound the RBD after overexpression in Chinese hamster ovary (CHO) cells as fusions to the Fc domain of human IgG1. The paper was published February 5, 2021 in the peer-reviewed journal, New Biotechnology, and can be found below.
Tango Biosciences publishes work on SARS-CoV-2 virus
More News and Events
-
NIH Awards New SBIR Grant
The National Institutes of Health (NIH) awarded a phase I SBIR grant to Tango Biosciences in July 2025. This award will support the application of Tango Biosciences’ proprietary Avidimer platform for the development of protein tools that enhance the discovery of proximity inducing modalities such as molecular glues. The Avidimers developed in this program will generate proof-of-concept […]
-
News
Tango Biosciences Appoints Zachary Gurard-Levin, PhD to Board of Directors
Appointment Brings Over Ten Years as a CRO Executive Tango Biosciences, Inc., the premier contract research organization for custom affinity reagents by phage display, announced the appointment of Zachary Gurard-Levin, PhD, to its board of directors effective immediately. Gurard-Levin brings over two decades of experience in assay development and driving successful research programs for biotech […]
-
Event
ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Chicago, IL | May 12-15, 2025 Join Tango Biosciences at ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025! Booth CP3 This meeting attracts a highly targeted audience composed of experts and researchers in drug discovery and development. Visit the Tango Biosciences booth to talk to our experts in peptide therapeutics discovery, targeted protein degradation for PROTACs and molecular glues, […]